Compounds identified by virtual docking to a tetrameric EGFR extracellular domain can modulate Grb2 internalization

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Ramirez, Ursula D ^a   Nikonova, Anna S ^a   Liu, Hanqing ^a   Pecherskaya, Anna ^a   Lawrence, Sarah H ^a   Serebriiskii, Ilya G ^a,b   Zhou, Yan ^a   Robinson, Matthew K ^a   Einarson, Margret B ^a   Golemis, Erica A ^a   Jaffe, Eileen K ^a  

^a FOX CHASE CANCER CENTER   (United States)

^b KAZAN FEDERAL UNIVERSITY   (Russian Federation)

Author keywords

Epidermal growth factor receptor; Extracellular domain; Grb2; Protein multimerization

Indexed keywords

ANTINEOPLASTIC AGENT; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; F 09220900; F 12600014; F 21450053; F 25730380; F 25990073; F 27382186; F 31090096; F 32630061; F 33853143; F 34060664; F 52300424; F 52530138; GROWTH FACTOR RECEPTOR BOUND PROTEIN 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; TETRAMER; UNCLASSIFIED DRUG; GRB2 PROTEIN, HUMAN; PROTEIN KINASE INHIBITOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOMA CELL; CELL VIABILITY; COMPUTER MODEL; CONTROLLED STUDY; DRUG DESIGN; DRUG IDENTIFICATION; DRUG TARGETING; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HIGH THROUGHPUT SCREENING; INTERNALIZATION; LIGAND BINDING; MATHEMATICAL COMPUTING; MOLECULAR DOCKING; MOLECULAR DYNAMICS; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; PROTEIN STABILITY; PROTEIN TRANSPORT; REACTION OPTIMIZATION; VIRTUAL REALITY; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; HEAD AND NECK NEOPLASMS; HUMAN; METABOLISM; PHOSPHORYLATION; PRECLINICAL STUDY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; CELL SURVIVAL; CETUXIMAB; DRUG EVALUATION, PRECLINICAL; ERLOTINIB HYDROCHLORIDE; GRB2 ADAPTOR PROTEIN; HEAD AND NECK NEOPLASMS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; PHOSPHORYLATION; PROTEIN INTERACTION DOMAINS AND MOTIFS; PROTEIN KINASE INHIBITORS; PROTEIN TRANSPORT; RECEPTOR, EPIDERMAL GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 84930666116     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1415-6     Document Type: Article

References (46)

1. Sibilia M, Fleischmann A, Behrens A, Stingl L, Carroll J, Watt FM, et al. The EGF receptor provides an essential survival signal for SOS-dependent skin tumor development. Cell. 2000;102(2):211-20.
2. Navas C, Hernandez-Porras I, Schuhmacher AJ, Sibilia M, Guerra C, Barbacid M. EGF receptor signaling is essential for k-ras oncogene-driven pancreatic ductal adenocarcinoma. Cancer Cell. 2012;22(3):318-30.
3. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, Bigner DS, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992;89(7):2965-9.
4. Hopper-Borge EA, Nasto RE, Ratushny V, Weiner LM, Golemis EA, Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies. Expert Opin Ther Targets. 2009;13(3):339-62.
5. Gan HK, Burgess AW, Clayton AH, Scott AM. Targeting of a conformationally exposed, tumor-specific epitope of EGFR as a strategy for cancer therapy. Cancer Res. 2012;72(12):2924-30.
6. Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, et al. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib. Clin Cancer Res. 2011;17(8):2521-7.
7. Weickhardt AJ, Price TJ, Chong G, Gebski V, Pavlakis N, Johns TG, et al. Dual targeting of the epidermal growth factor receptor using the combination of cetuximab and erlotinib: preclinical evaluation and results of the phase II DUX study in chemotherapy-refractory, advanced colorectal cancer. J Clin Oncol. 2012;30(13):1505-12.
8. Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harbor perspectives in biology. 2014;6(4):a020768.
9. Needham SR, Zanetti-Domingues LC, Hirsch M, Rolfe DJ, Tynan CJ, Roberts SK, et al. Structure-function relationships and supramolecular organization of the EGFR (epidermal growth factor receptor) on the cell surface. Biochem Soc Trans. 2014;42(1):114-9.
10. Burgess AW, Cho HS, Eigenbrot C, Ferguson KM, Garrett TP, Leahy DJ, et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors. Mol Cell. 2003;12(3):541-52.
11. Ferguson KM, Berger MB, Mendrola JM, Cho HS, Leahy DJ, Lemmon MA. EGF activates its receptor by removing interactions that autoinhibit ectodomain dimerization. Mol Cell. 2003;11(2):507-17.
12. Alvarado D, Klein DE, Lemmon MA. Structural basis for negative cooperativity in growth factor binding to an EGF receptor. Cell. 2010;142(4):568-79.
13. Wang Q, Villeneuve G, Wang Z. Control of epidermal growth factor receptor endocytosis by receptor dimerization, rather than receptor kinase activation. EMBO Rep. 2005;6(10):942-8.
14. Sawano A, Takayama S, Matsuda M, Miyawaki A. Lateral propagation of EGF signaling after local stimulation is dependent on receptor density. Dev Cell. 2002;3(2):245-57.
15. Ariotti N, Liang H, Xu Y, Zhang Y, Yonekubo Y, Inder K, et al. Epidermal growth factor receptor activation remodels the plasma membrane lipid environment to induce nanocluster formation. Mol Cell Biol. 2010;30(15):3795-804.
16. Clayton AH, Tavarnesi ML, Johns TG. Unligated epidermal growth factor receptor forms higher order oligomers within microclusters on A431 cells that are sensitive to tyrosine kinase inhibitor binding. Biochemistry. 2007;46(15):4589-97.
17. Clayton AH, Walker F, Orchard SG, Henderson C, Fuchs D, Rothacker J, et al. Ligand-induced dimer-tetramer transition during the activation of the cell surface epidermal growth factor receptor-A multidimensional microscopy analysis. J Biol Chem. 2005;280(34):30392-9.
18. Kozer N, Barua D, Orchard S, Nice EC, Burgess AW, Hlavacek WS, et al. Exploring higher-order EGFR oligomerisation and phosphorylation-a combined experimental and theoretical approach. Mol Biosyst. 2013;9(7):1849-63.
19. Mehra R, Serebriiskii IG, Dunbrack Jr RL, Robinson MK, Burtness B, Golemis EA. Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer. Drug resistance updates: reviews and commentaries in antimicrobial and anticancer chemotherapy. 2011;14(6):260-79.
20. Kastner J, Loeffler HH, Roberts SK, Martin-Fernandez ML, Winn MD. Ectodomain orientation, conformational plasticity and oligomerization of ErbB1 receptors investigated by molecular dynamics. J Struct Biol. 2009;167(2):117-28.
21. Tynan CJ, Roberts SK, Rolfe DJ, Clarke DT, Loeffler HH, Kastner J, et al. Human epidermal growth factor receptor (EGFR) aligned on the plasma membrane adopts key features of Drosophila EGFR asymmetry. Mol Cell Biol. 2011;31(11):2241-52.
22. Murali R, Brennan PJ, Kieber-Emmons T, Greene MI. Structural analysis of p185c-neu and epidermal growth factor receptor tyrosine kinases: oligomerization of kinase domains. Proc Natl Acad Sci U S A. 1996;93(13):6252-7.
23. Kozer N, Barua D, Henderson C, Nice EC, Burgess AW, Hlavacek WS, et al. Recruitment of the adaptor protein Grb2 to EGFR tetramers. Biochemistry. 2014;53(16):2594-604.
24. Chen CH, Chernis GA, Hoang VQ, Landgraf R. Inhibition of heregulin signaling by an aptamer that preferentially binds to the oligomeric form of human epidermal growth factor receptor-3. Proc Natl Acad Sci U S A. 2003;100(16):9226-31.
25. Zhang Q, Park E, Kani K, Landgraf R. Functional isolation of activated and unilaterally phosphorylated heterodimers of ERBB2 and ERBB3 as scaffolds in ligand-dependent signaling. Proc Natl Acad Sci U S A. 2012;109(33):13237-42.
26. Landgraf R, Eisenberg D. Heregulin reverses the oligomerization of HER3. Biochemistry. 2000;39(29):8503-11.
27. Park E, Baron R, Landgraf R. Higher-order association states of cellular ERBB3 probed with photo-cross-linkable aptamers. Biochemistry. 2008;47(46):11992-2005.
28. Friesner RA, Banks JL, Murphy RB, Halgren TA, Klicic JJ, Mainz DT, et al. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy. J Med Chem. 2004;47(7):1739-49.
29. Friesner RA, Murphy RB, Repasky MP, Frye LL, Greenwood JR, Halgren TA, et al. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J Med Chem. 2006;49(21):6177-96.
30. Halgren TA, Murphy RB, Friesner RA, Beard HS, Frye LL, Pollard WT, et al. Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening. J Med Chem. 2004;47(7):1750-9.
31. Avraham R, Yarden Y. Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 2011;12(2):104-17.
32. Sukhanova A, Gorin A, Serebriiskii IG, Gabitova L, Zheng H, Restifo D, et al. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation. Cancer discovery. 2013;3(1):96-111.
33. Zheng Y, Zhang C, Croucher DR, Soliman MA, St-Denis N, Pasculescu A, et al. Temporal regulation of EGF signalling networks by the scaffold protein Shc1. Nature. 2013;499(7457):166-71.
34. Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, et al. VAV3 mediates resistance to breast cancer endocrine therapy. Breast cancer research: BCR. 2014;16(3):R53.
35. Dayekh K, Johnson-Obaseki S, Corsten M, Villeneuve PJ, Sekhon HS, Weberpals JI, et al. Monensin inhibits epidermal growth factor receptor trafficking and activation: synergistic cytotoxicity in combination with EGFR inhibitors. Mol Cancer Ther. 2014;13(11):2559-71.
36. Prewett M, Rockwell P, Rockwell RF, Giorgio NA, Mendelsohn J, Scher HI, et al. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol. 1996;19(6):419-27.
37. Prewett M, Rockwell P, Rose C, Goldstein N. Anti-tumor and cell cycle responses in KB cells treated with a chimeric anti-EGFR monoclonal antibody in combination with cisplatin. Int J Oncol. 1996;9(2):217-24.
38. Kwak EL, Sordella R, Bell DW, Godin-Heymann N, Okimoto RA, Brannigan BW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005;102(21):7665-70.
39. Astsaturov I, Ratushny V, Sukhanova A, Einarson MB, Bagnyukova T, Zhou Y, et al. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies. Sci Signal. 2010;3(140):ra67.
40. Li S, Schmitz KR, Jeffrey PD, Wiltzius JJ, Kussie P, Ferguson KM. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell. 2005;7(4):301-11.
41. Jaffe EK. Impact of quaternary structure dynamics on allosteric drug discovery. Curr Top Med Chem. 2013;13(1):55-63.
42. Gabizon R, Friedler A. Allosteric modulation of protein oligomerization: an emerging approach to drug design. Frontiers in chemistry. 2014;2:9.
43. Bornholdt ZA, Noda T, Abelson DM, Halfmann P, Wood MR, Kawaoka Y, et al. Structural rearrangement of ebola virus VP40 begets multiple functions in the virus life cycle. Cell. 2013;154(4):763-74.
44. Lawrence SH, Ramirez UD, Tang L, Fazliyez F, Kundrat L, Markham GD, et al. Shape shifting leads to small-molecule allosteric drug discovery. Chem Biol. 2008;15(6):586-96.
45. Jaffe EK, Lawrence SH. Allostery and the dynamic oligomerization of porphobilinogen synthase. Arch Biochemi Biophys. 2012;519(2):144-53.
46. Lawrence SH, Ramirez UD, Selwood T, Stith L, Jaffe EK. Allosteric inhibition of human porphobilinogen synthase. J Biol Chem. 2009;284(51):35807-17.